

BAR Rapid Test Dipstick (Urine) Package Insert

REF DBA-101/111 English

A rapid test for the qualitative detection of Barbiturates in human urine. For medical and other professional in vitro diagnostic use only.

[INTENDED USE]

The BAR Rapid Test Dipstick (Urine) is a lateral flow chromatographic immunoassay for the detection of Barbiturates in urine at a cut-off concentration of 300 ng/mL. This test will detect other related compounds, please refer to the Analytical Specificity table in this package insert.

This assay provides only a qualitative, preliminary analytical test result. A more specific alternate chemical method must be used in order to obtain a confirmed analytical result. Gas chromatography/ mass spectrometry (GC/MS) is the preferred confirmatory method. Clinical consideration and professional judgment should be applied to any drug of abuse test result, particularly when preliminary

Barbiturates are central nervous system depressants. They are used therapeutically as sedatives, hypnotics, and anticonvulsants. Barbiturates are almost always taken orally as capsules or tablets. The effects resemble those of intoxication with alcohol. Chronic use of Barbiturates leads to tolerance and physical dependence. Short acting Barbiturates taken at 400 mg/day for 2-3 months produce a clinically significant degree of physical dependence. Withdrawal symptoms experienced during periods of drug abstinence can be severe enough to cause death. Only a small amount (less than 5%) of most Barbiturates are excreted unaltered in the urine. The detection period for the Barbiturates in the urine is 4-7 days

The BAR Rapid Test Dipstick (Urine) is a rapid urine-screening test that can be performed without the use of an instrument. The test utilizes a monoclonal antibody to selectively detect elevated levels of Barbiturates in urine. The BAR Rapid Test Dipstick (Urine) yields a positive result when the Barbiturates in urine exceeds the cut-off level

[PRINCIPLE]

The BAR Rapid Test Diostick (Urine) is an immunoassay based on the principle of competitive binding Drugs that may be present in the urine specimen compete against the drug conjugate for binding sites on the antibody

During testing, a urine specimen migrates upward by capillary action. Barbiturates, if present in the urine specimen below the cut-off level, will not saturate the binding sites of the antibody in the test. The antibody coated particles will then be captured by immobilized Barbiturate-protein conjugate and a visible colored line will show up in the test line region. The colored line will not form in the test line region if the Barbiturate level exceeds the cut-off level because it will saturate all the binding sites of anti-Barbiturate antibodies

A drug-positive urine specimen will not generate a colored line in the test line region because of drug competition, while a drug-negative urine specimen or a specimen containing a drug concentration less than the cut-off will generate a line in the test line region. To serve as a procedural control, a colored line will always appear at the control line region indicating that proper volume of specimen has been added and membrane wicking has occurred.

[REAGENTS]

The test contains mouse monoclonal anti-Barbiturates antibody coupled particles and Barbiturates-protein conjugate. A goat antibody is employed in the control line system.

[PRECAUTIONS]

- For medical and other professional in vitro diagnostic use only. Do not use after the expiration date.
- . The test should remain in the sealed pouch until use.
- · All specimens should be considered potentially hazardous and handled in the same manner as an
- . The used test should be discarded according to local regulations.

[STORAGE AND STABILITY]

Store as packaged at room temperature or refrigerated (2-30°C). The test is stable through the expiration date printed on the sealed pouch or label of the closed canister. The test must remain in the sealed pouch or closed canister until use. DO NOT FREEZE. Do not use beyond the expiration date. NOTE: Once the canister has been opened, the remaining test(s) are stable for 50 days only.

SPECIMEN COLLECTION AND PREPARATION

Urine Assav

The urine specimen must be collected in a clean and dry container. Urine collected at any time of the day may be used. Urine specimens exhibiting visible particles should be centrifuged, filtered, or allowed to settle to obtain a clear specimen for testing.

Specimen Storage

Urine specimens may be stored at 2-8°C for up to 48 hours prior to testing. For prolonged storage, specimens may be frozen and stored below -20°C. Frozen specimens should be thawed and mixed before testing

[MATERIALS]

Materials Provided

· Test Dipsticks · Package insert


Materials Required But Not Provided

· Specimen collection container Timer

[DIRECTIONS FOR USE]

Allow the test, urine specimen, and/or controls to reach room temperature (15-30°C) prior to

- 1. Bring the pouch to room temperature before opening it. Remove the Rapid Test Dipstick from the sealed pouch and use it within one hour.
- 2. With arrows pointing toward the urine specimen, immerse the rapid test dipstick vertically in the urine specimen for at least 10-15 seconds. Do not pass the maximum line (MAX) on the Rapid Test Dipstick when immersing the strip. See the illustration below



3. Place the rapid test dipstick on a non-absorbent flat surface, start the timer and wait for the colored line(s) to appear. Read results at 5 minutes. Do not interpret the result after 10 minutes.

[INTERPRETATION OF RESULTS]

(Please refer to the illustration above)

NEGATIVE:* Two lines appear. One colored line should be in the control line region (C), and another apparent colored line should be in the test line region (T). This negative result indicates that the Barbiturate concentration is below the detectable cut-off level

*NOTE: The shade of color in the test line region (T) may vary, but it should be considered negative whenever there is even a faint colored line

POSITIVE: One colored line appears in the control line region (C). No line appears in the test line region (T). This positive result indicates that the Barbiturate concentration exceeds the detectable cut-off level

INVALID: Control line fails to appear. Insufficient specimen volume or incorrect procedural techniques are the most likely reasons for control line failure. Review the procedure and repeat the test with a new test. If the problem persists, discontinue using the test kit immediately and contact your

[QUALITY CONTROL]

A procedural control is included in the test. A colored line appearing in the control line region (C) is considered an internal procedural control. It confirms sufficient specimen volume, adequate membrane wicking and correct procedural technique.

Control standards are not supplied with this kit; however, it is recommended that positive and negative controls be tested as good laboratory testing practice to confirm the test procedure and to verify proper

- 1. The BAR Rapid Test Dipstick (Urine) provides only a qualitative, preliminary analytical result. A secondary analytical method must be used to obtain a confirmed result. Gas chromatography/ mass spectrometry (GC/MS) is the preferred confirmatory method.^{2,3}
- 2. It is possible that technical or procedural errors, as well as other interfering substances in the urine specimen may cause erroneous results.
- 3. Adulterants, such as bleach and/or alum, in urine specimens may produce erroneous results regardless of the analytical method used. If adulteration is suspected, the test should be repeated with another urine specimen.
- 4. A positive result indicates presence of the drug or its metabolites but does not indicate level of intoxication, administration route or concentration in urine.
- 5. A negative result may not necessarily indicate drug-free urine. Negative results can be obtained when drug is present but below the cut-off level of the test.
- Test does not distinguish between drugs of abuse and certain medications.

[EXPECTED VALUES]

This negative result indicates that the Barbiturates concentration is below the detectable level of 300ng/ml. Positive result means the concentration of Barbiturates is above the level of 300ng/ml. The BAR Rapid Test Dipstick has a sensitivity of 300ng/ml

[PERFORMANCE CHARACTERISTICS]

Accuracy A side-by-side comparison was conducted using The BAR Rapid Test Dipstick and a commercially available BAR rapid test. Testing was performed on 95 clinical specimens previously collected from

subjects present for Drug Screen Testing. The following results were tabulated:

Method		Other BAR	Rapid Test	Total Results	
BAR Rapid Test Dipstick	Results	Positive	Negative	Total Results	
	Positive	37	0	37	
	Negative	0	58	58	
Total Resu	ilts	37	58	95	
% Agreement		>99.9%	>99.9%	>99.9%	

A side-by-side comparison was conducted using The BAR Rapid Test Dipstick and GC/MS at the cut-off of 300ng/mL. Testing was performed on 250 clinical specimens previously collected from subjects present for Drug Screen Testing. The following results were tabulated

subjecte procent for Br				
Method		GC	/MS	Total Results
BAR Rapid Test	Results	Positive	Negative	Total Results
Dipstick	Positive	98	2	100
Dipstick	Negative	4	146	150
Total Resu	ılts	102	148	250
% Agreem	ent	96.1%	98.6%	97.6%

Analytical Sensitivity

A drug-free urine pool was spiked with Secobarbital at the following concentrations: 0 ng/mL, 150 ng/mL, 225 ng/mL, 300 ng/mL, 375 ng/mL, 450 ng/mL, and 900ng/mL. The result demonstrates >99% accuracy at 50% above and 50% below the cut-off concentration. The data are summarized below

Secobarbital	Percent of Cut-off	_	Visual Result			
Concentration (ng/mL)	Percent of Cut-off	n	Negative	Positive		
0	0	30	30	0		
150	0 -50%		30	0		
225	-25%	30	27	3		
300	Cut-off	30	15	15		
375	+25%	30	3	27		
450 +50%		30	0	30		
900	3X	30	0	30		

Analytical Specificity

The following table lists compounds that are positively detected in urine by the BAR Rapid Test

Dipolick (Office) at 5 ffill	iulos.		
Compound	Concentration(ng/mL)	Compound	Concentration
Amobarbital	5,000	Cyclopentobarbit	30,000
5,5-Diphenylhyda	8,000	Pentobarbital	8,000
Allobarbital	600	Alphenol	600
Barbital	8,000	Aprobarbital	500
Talbutal	200	Butabarbital	200
Butalbital	8,000	Butethal	500
Phenobarbital	300	Secobarbital	300

Precision

A study was conducted at three hospitals by laypersons using three different lots of product to demonstrate the within run, between run and between operator precision. An identical panel of coded specimens, containing no Secobarbital, 25% Secobarbital above and below the cut-off, and 50% Secobarbital above and below the 300 ng/mL cut-off was provided to each site. The following results were tabulated:

Secobarbital	n	Site A		Sit	e B	Site C	
Concentration (ng/mL)	per Site	-	+	-	+	-	+
0	10	10	0	10	0	10	0
150	10	10	0	10	0	10	0
225	10	9	1	8	2	9	1
375	10	2	8	1	9	2	8
450	10	0	10	0	10	0	10

Effect of Urinary Specific Gravity

Fifteen urine specimens of normal, high, and low specific gravity ranges were spiked with 150 ng/mL and 450 ng/mL of Secobarbital respectively. The BAR Rapid Test Dipstick (Urine) was tested in duplicate using the fifteen neat and spiked urine specimens. The results demonstrate that varying ranges of urinary specific gravity do not affect the test results.

Effect of Urinary pH

The pH of an aliquoted negative urine pool was adjusted to a pH range of 5 to 9 in 1 pH unit increments and spiked with Secobarbital to 150 ng/mL and 450 ng/mL. The spiked, pH-adjusted urine was tested with The BAR Rapid Test Dipstick (Urine) in duplicate. The results demonstrate that varying ranges of pH do not interfere with the performance of the test.

Cross-Reactivity

A study was conducted to determine the cross-reactivity of the test with compounds in either drug-free urine or Barbiturates positive urine. The following compounds show no cross-reactivity when tested with The BAR Rapid Test Dipstick (Urine) at a concentration of 100 μg/mL.

	Non Cross-Read	cting Compounds	
Acetaminophenol	Diazepam	MDE	Phenylpropanolan
Acetophenetidin	Diclofenac	Meperidine	Prednisolone
N-Acetylprocainamide	Diflunisal	Meprobamate	Prednisone
Acetylsalicylic acid	Digoxin	Methadone	Procaine
Aminopyrine	Diphenhydramine	L-Methamphetamine	Promazine
Amitryptyline	Doxylamine	Methoxyphenamine	Promethazine
Amoxicillin	Ecgonine hydrochloride	(±) - 3,4-Methylenedioxy-	D,L-Propranolol
Ampicillin	Ecgonine methylester	amphetamine	D-Propoxyphene
L-Ascorbic acid	(-) -ψ-Ephedrine	(±) - 3,4-Methylenedioxy	D-Pseudoephedrin
D,L-Amphetamine sulfate	[1R,2S] (-) Ephedrine	methmphetamine	Quinacrine
Apomorphine	L - Epinephrine	Morphine-3-β-D glucuronide	Quinidine
Aspartame	Erythromycin	Morphine Sulfate	Quinine
Atropine	β-Estradiol	Nalidixic acid	Ranitidine
Benzilic acid	Estrone-3-sulfate	Naloxone	Salicylic acid
Benzoic acid	Ethyl-p-aminobenzoate	Naltrexone	Serotonin
Benzoylecgonine	Fenoprofen	Naproxen	Sulfamethazine
Benzphetamine	Furosemide	Niacinamide	Sulindac
Bilirubin	Gentisic acid	Nifedipine	Temazepam
(±) - Brompheniramine	Hemoglobin	Norcodein	Tetracycline
Caffeine	Hydralazine	Norethindrone	Tetrahydrocortisor
Cannabidiol	Hydrochlorothiazide	D-Norpropoxyphene	3-Acetate
Cannabinol	Hydrocodone	Noscapine	Tetrahydrocortisor
Chloralhydrate	Hydrocortisone	D,L-Octopamine	3-(β-D-glucuronid
Chloramphenicol	O-Hydroxyhippuric acid	Oxalic acid	Tetrahydrozoline
Chlorothiazide	p-Hydroxyamphetamine	Oxazepam	Thiamine
(±) - Chlorpheniramine	p-Hydroxy-	Oxolinic acid	Thioridazine
Chlorpromazine	methamphetamine	Oxycodone	D,L-Tyrosine
Chlorquine	3-Hydroxytyramine	Oxymetazoline	Tolbutamide
Cholesterol	Ibuprofen	Papaverine	Triamterene
Clomipramine	Imipramine	Penicillin-G	Trifluoperazine
Clonidine	Iproniazid	Pentazocine hydrochloride	Trimethoprim
Cocaethylene	(±) - Isoproterenol	Perphenazine	Trimipramine
Cocaine hydrochloride	Isoxsuprine	Phencyclidine	Tryptamine
Codeine	Ketamine	Phenelzine	D,L-Tryptophan
Cortisone	Ketoprofen	Phentermine	Tyramine
(-) Cotinine	Labetalol	Trans-2-phenylcyclo-	Uric acid
Creatinine	Levorphanol	propylamine hydrochloride	Verapamil
Deoxycorticosterone	Loperamide	L-Phenylephrine	Zomepirac
Dextromethorphan	Maprotiline	β-Phenylethylamine	

[BIBLIOGRAPHY]

- 1. Tietz NW, Textbook of Clinical Chemistry, W.B. Saunders Company, 1986; 1735
- 2. Baselt RC. Disposition of Toxic Drugs and Chemicals in Man. 2nd Ed. Biomedical Publ., Davis, CA. 1982: 488
- 3. Hawks RL, CN Chiang. Urine Testing for Drugs of Abuse. National Institute for Drug Abuse (NIDA), Research Monograph 73, 1986

Index of Symbols										
<u>^</u>	Attention, see instructions for use		Σ	Tests per kit		EC REP	Authorized Representative			
IVD	For in vitro diagnostic use only		\square	Use by		2	Do not reuse			
2°C - 30°C	Store between 2-30°C		LOT	Lot Number		REF	Catalog #			
(3)	Do not use if package is damaged									



Hangzhou AllTest Biotech Co., Ltd. #550. Yinhai Street

langzhou Economic & Technological Development Area Hangzhou - 310018, P. R. China www.altests.com.cn

Number Effective date:



48163 Muenste

145012704 2015-07-20

EC REP

Borkstrasse 10

MedNet GmbH